<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85496">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01662050</url>
  </required_header>
  <id_info>
    <org_study_id>FIL-RBAC500</org_study_id>
    <nct_id>NCT01662050</nct_id>
  </id_info>
  <brief_title>Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With Mantle Cell Lymphoma</brief_title>
  <acronym>FIL-RBAC500</acronym>
  <official_title>Phase II Study of Age‐Adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 study of standard R‐BAC (rituximab 375 mg/m2, bendamustine 70 mg/m2, ara‐c 800
      mg/m2) has been recently ultimated at the Vicenza Hematology Department involving several
      regional centers on both untreated and previously treated patients with Mantle Cell Lymphoma
      (MCL). An interim analysis conducted on 30 patients showed that rituximab + bendamustine +
      ara‐c combination had very good clinical activity, but a quite relevant hematological
      toxicity, especially in previously treated and older patients (Visco C, ICML 2011 Lugano
      Conference, Poster 236).

      Objectives:

      The primary objective is to determine the activity (complete remission rate according to
      Cheson 2007 criteria) and safety of age‐adjusted Rituximab‐Bendamustine‐Cytarabine (RBAC500)
      regimen at the end of treatment in older untreated patients with MCL.

      The secondary objectives are to determine:

        -  The rate of molecular response (characterized by labs of the FIL)

        -  The progression‐free survival (PFS)

        -  The overall survival (OS)

        -  The duration of responses (DOR)

        -  The rate of patients that complete the expected treatment schedule (6 courses)

        -  The rate of patients that are subject to dose reductions or delays
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study End points Primary efficacy end point of the study is the proportion of CR defined
      according to Cheson criteria (2007) at the end of treatment (6 or 4 cycles). Primary safety
      end point is the occurrence of any of the stop treatment criteria or of any episode of
      relevant toxicity, as above defined.

      Secondary end points are MRD defined response, OS, PFS and DOR (Cheson 2007). Molecular
      response is the proportion of patients with molecular rearrangements at baseline that become
      negative during treatment, measured by qualitative and quantitative PCR.

      OS is measured from enrollment until death from any cause. PFS is measured from the time of
      enrollment until disease progression, relapse or death from any cause. DOR is measured from
      the first assessment that documents response (CR or PR) to the date of disease relapse or
      progression. Minimum follow up required for all patients will be 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>complete remission rate at the end of treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to determine the activity [complete remission rate (CR) according to Cheson 2007 criteria]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity will be represented by the occurrence of any of the stop treatment criteria or of any episode of relevant toxicity</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Relevant toxicity:
Grade 4 cytopenia lasting for more than 6 days or Grade 3-4 non-hematologic toxicity or Febrile neutropenia lasting for more than 3 consecutive days.
Stop treatment criteria:
Occurrence of relevant toxicity for two subsequent or consecutive cycles.
Grade 3-4 hematological or non-hematological toxicity on day +28 of a cycle not resolving within two weeks.
Grade 3-4 hematological or non-hematological toxicity on day +28 of a cycle after 25% dose reduction.
Patient refusal to procede with further cycles due to perceived excessive toxicity.
Any unpredictable drug related event that suggests against study continuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of molecular response</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the rate of molecular response (characterized by labs of the FIL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the progression-free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the progression-free survival (PFS)is defined as the time from enrollment to complete remission with disappearance of all evidence of disease, disease progression or relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the overall survival (OS) is defined as the time from enrollment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of responses (DOR)</measure>
    <time_frame>30 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the duration of responses (DOR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of completion of treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>the rate of patients that complete the expected treatment schedule (6 courses)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of dose reductions or delays</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the rate of patients that are subject to dose reductions or delays</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One arm for all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab, Bendamustine, Cytarabine.</intervention_name>
    <description>6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated patients with MCL aged &gt; 65 years if they are FIT according to
             the geriatric CGA assessment.

          -  age 60-65 years not eligible to high-dose chemotherapy plus transplantation, FIT or
             UNFIT according to the geriatric CGA assessment.

          -  ECOG performance status ≤ 2.

          -  Positivity for cyclin D1 and SOX11 [the latter being mandatory in cases lacking
             cyclin D1- or t(11;14)-negative], CD20 and CD5.

          -  Adequate renal function (Creatinine clearance &gt; 40 mL/min), with preserved diuresis.

          -  Adequate liver function: alanine aminotransferase (ALT)/aspartate aminotransferase
             (AST) &lt; 2.5 x upper limit of normal (ULN) value, total bilirubin &lt; 2 mg/dL, unless
             directly attributable to the patient's tumor.

          -  Hepatitis B core antibody (HBcAb) positive/HBsAg negative/HBV-DNA negative patients
             may be enrolled if correct antiviral prophylaxis is administered at least 2 weeks
             before initiating protocol treatment.

          -  Written informed consent.

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) positive.

          -  Previous treatment for lymphoma

          -  Medical conditions or organ injuries that could interfere with administration of
             therapy.

          -  Active bacterial, viral, or fungal infection requiring systemic therapy.

          -  Seizure disorders requiring anticonvulsant therapy.

          -  Severe chronic obstructive pulmonary disease with hypoxemia.

          -  History of severe cardiac disease: New York Heart Association (NYHA) functional class
             III-IV, myocardial infarction within 6 months, ventricular tachyarrhythmias,
             dilatative cardiomyopathy, or unstable angina.

          -  Uncontrolled diabetes mellitus.

          -  Active secondary malignancy.

          -  Known hypersensitivity or anaphylactic reactions to murine antibodies and proteins,
             to Bendamustine or mannitol.

          -  Major surgery within 4 weeks of study Day 1.

          -  HBsAg+

          -  HCVAb+ patients with active viral replication (HCV-RNA+ with AST &gt; 2 x normal limit)

          -  Any co-existing medical or psychological condition that would preclude participation
             in the study or compromise the patient's ability to give informed consent, or that
             may affect the interpretation of the results, or render the patient at high risk from
             treatment complications.

          -  CNS involvement (a diagnostic lumbar puncture will be performed in patients with the
             blastoid variant of MCL)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS Ospedale Oncologico</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Attilio Guarini, MD</last_name>
      <phone>+39 080-5555905</phone>
      <email>attilioguarini@oncologico.bari.it</email>
    </contact>
    <investigator>
      <last_name>Attilio Guarini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Policlinico Consorziale</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgina Specchia, MD</last_name>
      <phone>+39 080-5593471</phone>
      <email>g.specchia@ematba.uniba.it</email>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Re, MD</last_name>
      <phone>+39 030-3995438</phone>
      <email>sandrore@aruba.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Re, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia Ospedale &quot;San Nicola Pellegrino&quot; ASL BAT</name>
      <address>
        <city>Trani</city>
        <state>BT</state>
        <zip>70031</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <phone>+39 0883-483269</phone>
      <email>tarantini-giuseppe@libero.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Tarantini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Giuseppina Cabras, MD</last_name>
      <phone>+39 070-6095221</phone>
      <email>cabras.giuseppina@tiscali.it</email>
    </contact>
    <investigator>
      <last_name>Maria Giuseppina Cabras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emanuele Angelucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Valduce</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erika Ravelli, MD</last_name>
      <phone>031-324381</phone>
      <email>erikaravelli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Erika Ravelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Garibaldi Nesima</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ugo Consoli, MD</last_name>
      <phone>+39 095-7595057</phone>
      <email>ugo.consoli@tin.it; ematologia.nesima@alice.it</email>
    </contact>
    <investigator>
      <last_name>Ugo Consoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Careggi</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Rigacci</last_name>
      <phone>+39 055-7947358</phone>
      <email>luigirigacci@unifi.it; benedettapuccini@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Rigacci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Michele Carella, MD</last_name>
      <phone>+39 010-513731</phone>
      <email>angelomichele.carella@hsanmartino.it</email>
    </contact>
    <investigator>
      <last_name>Angelo Michele Carella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Filippo Ballerini, MD</last_name>
      <phone>+39 010-5552645</phone>
      <email>ballerini@unige.it</email>
    </contact>
    <investigator>
      <last_name>Filippo Ballerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PO Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
      <phone>+39 0832-661923</phone>
      <email>direnzo.ematolecce@libero.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardinale G. Panico</name>
      <address>
        <city>Tricase</city>
        <state>LE</state>
        <zip>73039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincenzo Pavone, MD</last_name>
      <phone>+39 0833-773460</phone>
      <email>salentoematologia@piafondazionepanico.it; linda.ferrara@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Pavone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asur - Zona Territoriale 8</name>
      <address>
        <city>Civitanova Marche</city>
        <state>MC</state>
        <zip>62012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riccardo Centurioni, MD</last_name>
      <phone>+39 0733 823065</phone>
      <email>riccardo.centurioni@sanita.marche.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo Centurioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Policlinico Universitario</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Musolino, MD</last_name>
      <phone>+39 0902212355/64</phone>
      <email>cmusolino@unime.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Musolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Baldini, MD</last_name>
      <phone>+39 02 - 55033334/3462</phone>
      <email>lubaldini@policlinico.mi.it</email>
    </contact>
    <investigator>
      <last_name>Luca Baldini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Niguarda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Rusconi, MD</last_name>
      <phone>+39 02 - 64442668</phone>
      <email>chiara.rusconi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Rusconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Carlo Borromeo di Milano Unità Semplice di Trapianto Midollo - A.O.S.Carlo Borromeo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucilla Tedeschi, MD</last_name>
      <phone>+39 02-40222104</phone>
      <email>tedeschi.lucilla@sancarlo.mi.it</email>
    </contact>
    <investigator>
      <last_name>Lucilla Tedeschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osp. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Pogliani, MD</last_name>
      <phone>039-2339435</phone>
      <email>enrico.pogliani@unimib.it; marziaborsetto@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Pogliani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>+39 02-82244536</phone>
      <email>monica.balzarotti@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Modenese (COM)</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samantha Pozzi, MD</last_name>
      <phone>+39 059-4225407</phone>
      <email>samantha.pozzi@unimore.it; soniamastronardi@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Samantha Pozzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;La Maddalena&quot;</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurizio Musso, MD</last_name>
      <phone>091-6806524(3)</phone>
      <email>rscalone@libero.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Musso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Patti, MD</last_name>
      <phone>+39 091-6884002</phone>
      <email>k.patti@ospedaliriunitipalermo.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniele Vallisa, MD</last_name>
      <phone>+39 0523-303701/719</phone>
      <email>d.vallisa@auslpc.it</email>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Zambello, MD</last_name>
      <email>r.zambello@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Renato Zambello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio ospedaliero di Pescara</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli, MD</last_name>
      <phone>+39 085 - 4252838</phone>
      <email>f.angrilli@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Angrilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRO Aviano</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <email>mspina@cro.it; eravaioli@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo,</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Arcaini, MD</last_name>
      <phone>0382-8745190</phone>
      <email>luca.arcaini@unipv.it;ematologia.coltcell@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Luca Arcaini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osp. S. Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani, MD</last_name>
      <phone>+39 0544-286223</phone>
      <email>monica.tani@ausl.ra.it; b.vertogen@ausl.ra.it</email>
    </contact>
    <investigator>
      <last_name>Monica Tani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Bianchi Melacrino Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
      <phone>+39 0522-296618</phone>
      <email>cstelit@libero.it; elkis862@libero.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Arcispedale &quot;S.Maria Nuova&quot;</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Merli, MD</last_name>
      <phone>+39 0522-296618</phone>
      <email>merli.francesco@asmn.re.it ; caterina.mammi@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Martelli, MD</last_name>
      <phone>+39 06-857951</phone>
      <email>martelli@bce.uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Martelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Andriani, MD</last_name>
      <phone>+39 06 58446826</phone>
      <email>alessandro.andriani@tin.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Andriani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo Forlanini</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignazio Majolino</last_name>
      <phone>+39 06-58703495</phone>
      <email>imajolino@scamilloforlanini.rm.it</email>
    </contact>
    <investigator>
      <last_name>Ignazio Majolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Giovanni Addolorata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00184</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciana Annino, MD</last_name>
      <phone>+39 06-77055482</phone>
      <email>paola.anticoli@inwind.it; lannino@hsangiovanni.roma.it</email>
    </contact>
    <investigator>
      <last_name>Luciana Annino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale degli Infermi di Rimini</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalia Molinari, MD</last_name>
      <phone>+39 0541705423</phone>
      <email>annalia.molinari@auslrn.it</email>
    </contact>
    <investigator>
      <last_name>Annalia Molinari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 18</name>
      <address>
        <city>Rovigo</city>
        <state>RO</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rossella Paolini, MD</last_name>
      <email>oncologia.ro@azisanrovigo.it</email>
    </contact>
    <investigator>
      <last_name>Rossella Paolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osp. Umberto I</name>
      <address>
        <city>Nocera Inferiore</city>
        <state>SA</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfonso M. D'Arco, MD</last_name>
      <phone>+39 081-9213370</phone>
      <email>medint.nocera@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alfonso M. D'Arco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Giovanni di Dio e Ruggi d'Aragona</name>
      <address>
        <city>Salerno</city>
        <state>SA</state>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmine Selleri, MD</last_name>
      <phone>+39 089-673157</phone>
      <email>cselleri@unisa.it; luana.tortora@sangiovannieruggi.it</email>
    </contact>
    <investigator>
      <last_name>Carmine Selleri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera Univ. Senese</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Fabbri, MD</last_name>
      <email>fabbri7@unisi.it ;benedetta.lucani@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alberto Fabbri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL TO4</name>
      <address>
        <city>Ciriè-Ivrea-Chivasso</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Freilone, MD</last_name>
      <email>rfreilone@aslto4.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Roberto Freilone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Luigi Gonzaga,</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Parvis, MD</last_name>
      <phone>011-9026604/72</phone>
      <email>g.parvis@sanluigi.piemonte.it; czsanluigi@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Guido Parvis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.U. S. Giovanni Battista -Ematologia 2</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annalisa Chiappella, MD</last_name>
      <phone>+39 011-6335610</phone>
      <email>achiappella@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Annalisa Chiappella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU San Giovanni Battista-Ematologia 1</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Ladetto, MD</last_name>
      <phone>+39 011-6334264</phone>
      <email>marco.ladetto@unito.it;antonella.fiorillo@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Marco Ladetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S. Maria di Terni</name>
      <address>
        <city>Terni</city>
        <state>TR</state>
        <zip>05100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Marina Liberati, MD</last_name>
      <phone>+39 0744-205971</phone>
      <email>marinal@unipg.it;appolloniviviana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Marina Liberati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria di Udine</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Zaja, MD</last_name>
      <phone>+39 0432-559662</phone>
      <email>zaja.francesco@aoud.sanita.fvg.it;d'odorico.cristina@aoud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Zaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi - Oncologia</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graziella Pinotti, MD</last_name>
      <phone>+39 0332-278558</phone>
      <email>graziella.pinotti@ospedale.varese.it</email>
    </contact>
    <investigator>
      <last_name>Graziella Pinotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo e Fondazione Macchi - Ematologia</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Passamonti</last_name>
      <phone>+39 0332-393648</phone>
      <email>francesco.passamonti@ospedale.varese.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Passamonti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osp. S. Andrea Vercelli</name>
      <address>
        <city>Vercelli</city>
        <state>VC</state>
        <zip>13100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Santagostino, MD</last_name>
      <phone>+39 0161-593087</phone>
      <email>alberto.santagostino@aslvc.piemonte.it ;albemail@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Santagostino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile di Mirano</name>
      <address>
        <city>Mirano</city>
        <state>VE</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Bertoldero, MD</last_name>
      <email>giovanni.bertoldero@ulss13mirano.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Visco, MD</last_name>
      <phone>+39 0444-753626/3518</phone>
      <email>carlovisco@hotmail.com;silvia.finotto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carlo Visco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B. Rossi (Borgo Roma) Di Verona</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achille Ambrosetti, MD</last_name>
      <phone>+39 045-8124420/4797</phone>
      <email>achille.ambrosetti@univr.it</email>
    </contact>
    <investigator>
      <last_name>Achille Ambrosetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. SS. Antonio e Biagio e C. Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Salvi, MD</last_name>
      <phone>+39 0131206294</phone>
      <email>segreteria@filinf.it</email>
    </contact>
    <investigator>
      <last_name>Flavia Salvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprensorio sanitario di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atto Billio, MD</last_name>
      <phone>0471-908388</phone>
      <email>abillio@hotmail.com; emat@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Atto Billio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Campobasso</city>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianfranco Giglio, MD</last_name>
      <phone>+39 087-409448; +39 087-409446</phone>
      <email>gianfrancogiglio@alice.it</email>
    </contact>
    <investigator>
      <last_name>Gianfranco Giglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Pugliese-Ciacci</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Molica, MD</last_name>
      <phone>+39 0961-883001</phone>
      <email>smolica@libero.it</email>
    </contact>
    <investigator>
      <last_name>Stefano Molica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRST</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerardo Musuraca, MD</last_name>
      <phone>+39 0543-739100</phone>
      <email>g.musuraca@irst.emr.it; francesca.fabbri@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Gerardo Musuraca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università del Piemonte Orientale - Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
      <phone>0321/660655</phone>
      <email>gaidano@med.unipmn.it ; clara.deambrogi@med.unipmn.it</email>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>June 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCL</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Older</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bendamustine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
